Prosperity Consulting Group LLC Sells 276 Shares of Eli Lilly and Company $LLY

Prosperity Consulting Group LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,280 shares of the company’s stock after selling 276 shares during the quarter. Prosperity Consulting Group LLC’s holdings in Eli Lilly and Company were worth $7,234,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the period. Covestor Ltd grew its stake in shares of Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after acquiring an additional 85 shares during the period. Kaufman Rossin Wealth LLC bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $242,000. Finally, Opes Wealth Management LLC grew its position in Eli Lilly and Company by 6.6% in the 1st quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock worth $278,000 after purchasing an additional 21 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 3.9%

Shares of Eli Lilly and Company stock opened at $896.15 on Tuesday. The company has a market capitalization of $848.17 billion, a P/E ratio of 58.57, a P/E/G ratio of 1.21 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a fifty day moving average of $784.74 and a 200 day moving average of $772.35. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the company posted $1.18 earnings per share. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, Guggenheim reissued a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $940.00.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Daniel Skovronsky purchased 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.